• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
MyoKardia, Inc. operates as a biopharmaceutical company which engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. It offers MYK-46, an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy. The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
| Market Cap | 11.993 Billion | Shares Outstanding | 53.323 Million | Avg 30-day Volume | 1.086 Million |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -4.37 |
| Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -281.267 Million |
| Price to Book Value | 8.6032 | Operating Margin | 0.0 | Enterprise Value | 6.374 Billion |
| Current Ratio | 17.98 | EPS Growth | -0.096 | Quick Ratio | 17.735 |
| 1 Yr BETA | 0.9949 | 52-week High/Low | 0.0 / | Profit Margin | 0.0 |
| Operating Cash Flow Growth | 5.613 | Free Cash Flow to Firm (FCFF) TTM | -269.155 Million | Free Cash Flow to Equity (FCFE) TTM | -215.386 Million |
| Altman Z-Score | 22.0623 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
No longer subject to file | 2020-11-17 | 0 | |
|
No longer subject to file | 2020-11-17 | 0 | |
|
No longer subject to file | 2020-11-17 | 0 | |
|
No longer subject to file | 2020-11-17 | 0 | |
|
No longer subject to file | 2020-11-17 | 0 | |
|
MCDOWELL ROBERT SCOTT CHIEF SCIENTIFIC OFFICER |
|
No longer subject to file | 2020-11-17 | 0 |
|
GIANAKAKOS ANASTASIOS PRESIDENT AND CEO |
|
No longer subject to file | 2020-11-17 | 0 |
|
HARRIS TAYLOR C. CHIEF FINANCIAL OFFICER |
|
No longer subject to file | 2020-11-17 | 0 |
|
No longer subject to file | 2020-11-17 | 0 | |
|
BAUER JAKE CHIEF BUSINESS OFFICER |
|
No longer subject to file | 2020-11-17 | 0 |
|
FAIREY WILLIAM EVP, CHIEF COMMERCIAL OFFICER |
|
No longer subject to file | 2020-11-17 | 0 |
|
WAYNICK DENELLE J CHIEF LEGAL OFFICER |
|
No longer subject to file | 2020-11-17 | 0 |
|
LADD CYNTHIA J GENERAL COUNSEL |
|
0 | 2020-02-14 | 0 |
|
LEE JUNE EVP, CHIEF DEVELOPMENT OFFICER |
|
4,153 | 2019-09-23 | 0 |
|
No longer subject to file | 2019-02-13 | 0 | |
|
LAMBING JOSEPH SEE REMARKS |
|
0 | 2019-02-08 | 0 |
|
SEMIGRAN MARC CHIEF MEDICAL OFFICER |
|
0 | 2019-02-08 | 0 |
|
MCDOWELL ROBERT SCOTT CHIEF SCIENTIFIC OFFICER MCDOWELL ROBERT SCOTT CHIEF SCIENTIFIC OFFICER |
|
1,158 | 2019-01-07 | 0 |
|
No longer subject to file | 2018-03-07 | 0 | |
|
1,109,848 | 2018-03-07 | 0 | |
|
1,102,356 | 2018-01-03 | 0 | |
|
186,041 | 2017-12-31 | 0 | |
|
0 | 2017-06-14 | 0 | |
|
CHAN STEVEN SEE REMARKS |
|
0 | 2017-01-18 | 0 |
|
6,496 | 2016-11-29 | 0 | |
|
FOX JONATHAN C CHIEF MEDICAL OFFICER |
|
240,997 | 2016-04-29 | 0 |
|
THIRD ROCK VENTURES GP II, L.P. |
|
1,496,598 | 2015-11-03 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|---|---|---|---|
| American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund | MYOK | -1573.0 shares, $-114648.11 | 2019-12-31 | N-PORT |
| American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund | MYOK | -1004.0 shares, $-73176.54 | 2019-12-31 | N-PORT |
| American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund | MYOK | -7689.0 shares, $-400981.35 | 2019-09-30 | N-PORT |
| American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund | MYOK | -24995.0 shares, $-1303489.25 | 2019-09-30 | N-PORT |
| Trust for Professional Managers- Convergence Market Neutral Fund | MYOK | -665.0 shares, $-72777.6 | 2020-08-31 | N-PORT |
| FundVantage Trust- Gotham Enhanced Index Plus Fund | MYOK | -3.0 shares, $-140.64 | 2020-03-31 | N-PORT |
| FundVantage Trust- Gotham Index Plus All-Cap Fund | MYOK | -33.0 shares, $-1547.04 | 2020-03-31 | N-PORT |
